AKBA – Akebia Therapeutics Inc.
AKBA — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
7.27
Margin Of Safety %
4
Put/Call OI Ratio
0.17
EPS Next Q Diff
EPS Last/This Y
-0.08
EPS This/Next Y
-0.09
Price
0.91
Target Price
3.8
Analyst Recom
1.4
Performance Q
-22.89
Upside
-257.1%
Beta
0.19
Ticker: AKBA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | AKBA | 1.39 | 0.19 | 1.16 | 37785 |
| 2026-07-14 | AKBA | 1.41 | 0.19 | 0.02 | 37835 |
| 2026-07-15 | AKBA | 1.385 | 0.19 | 0.00 | 37848 |
| 2026-07-16 | AKBA | 1.41 | 0.19 | 1.18 | 38004 |
| 2026-07-17 | AKBA | 1.345 | 0.19 | 0.53 | 38030 |
| 2026-07-20 | AKBA | 1.285 | 0.15 | 4.19 | 29712 |
| 2026-07-21 | AKBA | 1.31 | 0.18 | 0.00 | 30425 |
| 2026-07-22 | AKBA | 1.265 | 0.18 | 0.27 | 30447 |
| 2026-07-23 | AKBA | 1.23 | 0.18 | 0.01 | 30852 |
| 2026-07-24 | AKBA | 1.225 | 0.18 | 0.03 | 30813 |
| 2026-07-27 | AKBA | 1.285 | 0.18 | 0.00 | 31071 |
| 2026-07-28 | AKBA | 1.28 | 0.18 | 0.00 | 31017 |
| 2026-07-29 | AKBA | 1.27 | 0.18 | 0.00 | 31053 |
| 2026-07-30 | AKBA | 1.36 | 0.18 | 0.03 | 31056 |
| 2026-07-31 | AKBA | 1.33 | 0.18 | 0.00 | 31105 |
| 2026-08-03 | AKBA | 1.31 | 0.18 | 0.00 | 31113 |
| 2026-08-04 | AKBA | 1.315 | 0.18 | 0.00 | 31164 |
| 2026-08-05 | AKBA | 1.28 | 0.18 | 0.01 | 31388 |
| 2026-08-07 | AKBA | 0.9068 | 0.17 | 0.02 | 32514 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | AKBA | 1.39 | -100.0 | - | -0.10 |
| 2026-07-14 | AKBA | 1.41 | -100.0 | - | -0.10 |
| 2026-07-15 | AKBA | 1.38 | -100.0 | - | -0.10 |
| 2026-07-16 | AKBA | 1.41 | -100.0 | - | -0.10 |
| 2026-07-17 | AKBA | 1.34 | -100.0 | - | -0.10 |
| 2026-07-20 | AKBA | 1.29 | -100.0 | - | -0.10 |
| 2026-07-21 | AKBA | 1.31 | -100.0 | - | -0.10 |
| 2026-07-22 | AKBA | 1.27 | -100.0 | - | -0.10 |
| 2026-07-23 | AKBA | 1.23 | -100.0 | - | -0.10 |
| 2026-07-24 | AKBA | 1.23 | -100.0 | - | -0.10 |
| 2026-07-27 | AKBA | 1.29 | -100.0 | - | -0.10 |
| 2026-07-28 | AKBA | 1.28 | -100.0 | - | -0.10 |
| 2026-07-29 | AKBA | 1.27 | -100.0 | - | -0.10 |
| 2026-07-30 | AKBA | 1.36 | -100.0 | - | -0.10 |
| 2026-07-31 | AKBA | 1.33 | -100.0 | - | -0.10 |
| 2026-08-03 | AKBA | 1.31 | -100.0 | - | -0.10 |
| 2026-08-04 | AKBA | 1.31 | -100.0 | - | -0.10 |
| 2026-08-05 | AKBA | 1.28 | -100.0 | - | -0.10 |
| 2026-08-06 | AKBA | 0.95 | -100.0 | - | -0.10 |
| 2026-08-07 | AKBA | 0.91 | 0.0 | - | -0.10 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | AKBA | -7.79 | -6.74 | 7.35 |
| 2026-07-14 | AKBA | -7.79 | -6.74 | 7.35 |
| 2026-07-15 | AKBA | -7.79 | -6.74 | 7.35 |
| 2026-07-16 | AKBA | -7.79 | -6.74 | 7.35 |
| 2026-07-17 | AKBA | -7.79 | -6.74 | 7.35 |
| 2026-07-20 | AKBA | -7.79 | -6.75 | 7.35 |
| 2026-07-21 | AKBA | -7.79 | -6.75 | 7.35 |
| 2026-07-22 | AKBA | -7.79 | -6.75 | 7.35 |
| 2026-07-23 | AKBA | -7.79 | -6.75 | 7.35 |
| 2026-07-24 | AKBA | -7.79 | -6.75 | 7.35 |
| 2026-07-27 | AKBA | -7.79 | -6.74 | 7.32 |
| 2026-07-28 | AKBA | -7.79 | -6.74 | 7.32 |
| 2026-07-29 | AKBA | -7.79 | -6.74 | 7.32 |
| 2026-07-30 | AKBA | -7.79 | -6.74 | 7.32 |
| 2026-07-31 | AKBA | -7.79 | -6.74 | 7.32 |
| 2026-08-03 | AKBA | -7.79 | -6.27 | 7.32 |
| 2026-08-04 | AKBA | -7.79 | -6.27 | 7.27 |
| 2026-08-05 | AKBA | 0.23 | -6.27 | 7.27 |
| 2026-08-06 | AKBA | 0.23 | -6.27 | 7.27 |
| 2026-08-07 | AKBA | 0.23 | -6.27 | 7.27 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.02
Avg. EPS Est. Current Quarter
-0.03
Avg. EPS Est. Next Quarter
-0.02
Insider Transactions
0.23
Institutional Transactions
-6.27
Beta
0.19
Average Sales Estimate Current Quarter
49
Average Sales Estimate Next Quarter
54
Fair Value
0.95
Quality Score
44
Growth Score
31
Sentiment Score
10
Actual DrawDown %
77.7
Max Drawdown 5-Year %
-92.5
Target Price
3.8
P/E
Forward P/E
PEG
P/S
1.15
P/B
9.88
P/Free Cash Flow
6.26
EPS
-0.11
Average EPS Est. Cur. Y
-0.1
EPS Next Y. (Est.)
-0.19
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-13.54
Relative Volume
2.1
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.12
EBIT Estimation
◆
AKBA
Healthcare
$0.91
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
27.4
Range 1M
8.9%
Sup Dist
4.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-620%
EPS NY
-88.9%
52W%
3.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+129.7% upside
Upside
+129.7%
Quality
44
MoS
4%
AKBA — P/E HistoricalBiotechnology
Akebia Therapeutics, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 194
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AKBA
Latest News
—
Caricamento notizie per AKBA…
stock quote shares AKBA – Akebia Therapeutics Inc. Stock Price stock today
news today AKBA – Akebia Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AKBA – Akebia Therapeutics Inc. yahoo finance google finance
stock history AKBA – Akebia Therapeutics Inc. invest stock market
stock prices AKBA premarket after hours
ticker AKBA fair value insiders trading